Bradley G. Somer MDMedical Oncologist; President, West Cancer Center and Research Institute; Associate Professor of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, Tennessee
Dr. Brad Somer, a medical oncologist in Memphis, Tennessee, is the President of the West Cancer Center and Research Institute, where he has practiced since 2002 after completing his fellowship training in hematology/oncology at the University of Pennsylvania Cancer Center in Philadelphia. He is one of the leaders of the most renowned multi-disciplinary comprehensive cancer center servicing the mid-south. He also serves as an assistant professor of hematology/oncology at the University of Tennessee Health Science Center.
Dr. Somer, is actively involved in clinical research in the gastrointestinal/genitourinary clinical trials program. He also serves on the NCCN panel for kidney cancer.
Dr. Somer earned his medical degree from the Albert Einstein College of Medicine in New York, with a Distinction in Research. He completed his internship and residency at the Hospital of the University of Pennsylvania in Philadelphia. While at the University of Pennsylvania, he served as assistant editor of OncoLink, a leading and award-winning cancer information website. He received his MBA at U Mass Amherst with a healthcare focus in conjunction with the American Association of Physician Leadership.
Assistant Professor, Hematology/Oncology, University of Tennessee Health Science Center; Senior Partner, West Clinic, Memphis, Tennessee
MD: Albert Einstein College of Medicine, New York
Fellowship (hematology/oncology):University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
DisclosuresDr. Somer does not have any disclosures.
Recent Contributions to PracticeUpdate:
- Active Surveillance for Localized Renal Masses
- Improving Tolerability of mXELIRI in mCRC: A Safety and Efficacy Comparison With FOLFIRI—A West Cancer Center Perspective
- Combining Checkpoint Inhibitors and VEGF Inhibitors for First-Line RCC: Early Data and Indications—A West Cancer Center Perspective
- Sunitinib Alone or After Nephrectomy in Renal Cell Carcinoma
- ASCO 2018: Abstract Recommendations From Dr. Brad Somer
- Biomarkers Define Probability of Receiving Second-Line Targeted Therapy in mRCC
- Nivolumab Plus Ipilimumab vs Sunitinib in Advanced RCC
- Cabozantinib Tops Everolimus for Patients With Advanced Renal Cell Carcinoma and Bone Metastases
- Safety and Efficacy of the HIF-2α Antagonist PT2385 in Patients With Previously Treated Advanced ccRCC
- FDA Grants Breakthrough Therapy Designation for Avelumab